Drugs that contain Patisiran Sodium
1. Drug name - ONPATTRO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8334373 | ALNYLAM PHARMS INC | Nuclease resistant double-stranded ribonucleic acid |
May, 2025
(2 years from now) | |
| US10240152 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of transthyretin |
Oct, 2029
(7 years from now) | |
| US8168775 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of transthyretin |
Oct, 2029
(7 years from now) | |
| US11079379 | ALNYLAM PHARMS INC | Methods of treating transthyretin (TTR) mediated amyloidosis |
Aug, 2035
(12 years from now) | |
| CN102186978B | ALNYLAM PHARMS INC | Compositions And Methods For Inhibiting Expression Of Transthyretin |
Oct, 2029
(7 years from now) | |
| CN103937793B | ALNYLAM PHARMS INC | Compositions And Methods For Inhibiting Expression Of Transthyretin |
Oct, 2029
(7 years from now) | |
| CN106834291A | ALNYLAM PHARMS INC | Compositions And Methods For Inhibiting Expression Of Transthyretin |
Oct, 2029
(7 years from now) | |
| CN106834291B | ALNYLAM PHARMS INC | Compositions And Methods For Inhibiting Expression Of Transthyretin |
Oct, 2029
(7 years from now) | |
| CN102186978A | ALNYLAM PHARMS INC | Compositions And Methods For Inhibiting Expression Of Transthyretin |
Oct, 2029
(7 years from now) | |
| CN103937793A | ALNYLAM PHARMS INC | Compositions And Methods For Inhibiting Expression Of Transthyretin |
Oct, 2029
(7 years from now) | |
| CN107106874B | ALNYLAM PHARMS INC | Method For Treating Transthyretin (Ttr) Mediated Amyloidosis |
Aug, 2035
(12 years from now) | |
| CN107106874A | ALNYLAM PHARMS INC | Method Of Treating Transthyretin (Ttr) Mediated Amyloidosis |
Aug, 2035
(12 years from now) | |
| IN307782B | ALNYLAM PHARMS INC | Compositions And Methods For Inhibiting Expression Of Transthyretin |
Oct, 2029
(7 years from now) | |
| IN201103301P4 | ALNYLAM PHARMS INC | Compositions And Methods For Inhibiting Expression Of Transthyretin |
Oct, 2029
(7 years from now) | |
| EP2399924B1 | ALNYLAM PHARMS INC | Nuclease Resistant Double-Stranded Ribonucleic Acid |
May, 2025
(2 years from now) | |
| EP2399924A3 | ALNYLAM PHARMS INC | Nuclease Resistant Double-Stranded Ribonucleic Acid |
May, 2025
(2 years from now) | |
| EP2399924A2 | ALNYLAM PHARMS INC | Nuclease Resistant Double-Stranded Ribonucleic Acid |
May, 2025
(2 years from now) | |
| EP2344639A2 | ALNYLAM PHARMS INC | Compositions And Methods For Inhibiting Expression Of Transthyretin |
Oct, 2029
(7 years from now) | |
| EP3354733A1 | ALNYLAM PHARMS INC | Compositions And Methods For Inhibiting Expression Of Transthyretin |
Oct, 2029
(7 years from now) | |
| EP2344639B1 | ALNYLAM PHARMS INC | Compositions And Methods For Inhibiting Expression Of Transthyretin |
Oct, 2029
(7 years from now) | |
| EP3354733B1 | ALNYLAM PHARMS INC | Compositions And Methods For Inhibiting Expression Of Transthyretin |
Oct, 2029
(7 years from now) | |
| EP2937418A1 | ALNYLAM PHARMS INC | Compositions And Methods For Inhibiting Expression Of Transthyretin |
Oct, 2029
(7 years from now) | |
| EP2937418B1 | ALNYLAM PHARMS INC | Compositions And Methods For Inhibiting Expression Of Transthyretin |
Oct, 2029
(7 years from now) | |
| EP3185957A2 | ALNYLAM PHARMS INC | Patisiran For Use In Treating Transthyretin Mediated Amyloidosis |
Aug, 2035
(12 years from now) | |
| EP3185957A4 | ALNYLAM PHARMS INC | Methods Of Treating Transthyretin (Ttr) Mediated Amyloidosis |
Aug, 2035
(12 years from now) | |
| EP3185957B1 | ALNYLAM PHARMS INC | Patisiran For Use In Treating Transthyretin Mediated Amyloidosis |
Aug, 2035
(12 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9943539 | ALNYLAM PHARMS INC | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations |
Nov, 2023
(1 year, 1 month from now) | |
| US9943538 | ALNYLAM PHARMS INC | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations |
Nov, 2023
(1 year, 1 month from now) | |
| US8642076 | ALNYLAM PHARMS INC | Lipid containing formulations |
Oct, 2027
(5 years from now) | |
| US8822668 | ALNYLAM PHARMS INC | Lipid formulations for nucleic acid delivery |
Apr, 2029
(6 years from now) | |
| US9364435 | ALNYLAM PHARMS INC | Lipid formulations for nucleic acid delivery |
Apr, 2029
(6 years from now) | |
| US8058069 | ALNYLAM PHARMS INC | Lipid formulations for nucleic acid delivery |
Apr, 2029
(6 years from now) | |
| US8492359 | ALNYLAM PHARMS INC | Lipid formulations for nucleic acid delivery |
Apr, 2029
(6 years from now) | |
| US11141378 | ALNYLAM PHARMS INC | Lipid formulations for nucleic acid delivery |
Apr, 2029
(6 years from now) | |
| US9234196 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of transthyretin |
Oct, 2029
(7 years from now) | |
| US8741866 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of transthyretin |
Oct, 2029
(7 years from now) | |
| US8802644 | ALNYLAM PHARMS INC | Lipid formulation |
Oct, 2030
(8 years from now) | |
| US8158601 | ALNYLAM PHARMS INC | Lipid formulation |
Nov, 2030
(8 years from now) | |
Treatment: Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 10MG BASE/5ML (EQ 2MG BASE/ML) | SOLUTION;INTRAVENOUS | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.